News

Touchless Emerald AI biosensor gets $1.1M funding boost from RSRT

The Rett Syndrome Research Trust (RSRT) has granted $1.1 million to help advance the development of the Emerald biosensor to accurately assess symptoms of Rett syndrome. This research award will contribute to the development of the biosensor, which uses artificial intelligence to assess irregular breathing, sleep disruptions, and…

FDA grants orphan drug designation to Ketarx for Rett syndrome

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Ketarx (racemic ketamine) for treating Rett Syndrome. The designation is awarded to products that show promise to prevent, diagnose, or treat rare diseases. Incentives for developers include seven years of market exclusivity after approval, potential…

Rett Syndrome Research Trust Helping to Advance HRP-12975

The Rett Syndrome Research Trust (RSRT) is supporting ongoing studies of HRP-12975, an investigational therapy for Rett syndrome, using mouse models of the disease. HRP-12975, being developed by Herophilus, is reported to be the first small molecule therapy with the potential to reverse MECP2 gene deficiency, the…

MECP2 Changes Dictate Nerve Cell Structure and Function in Study

Nerve cells derived from Rett syndrome patients showed alterations in structure, function, and network connectivity that depend on the severity of MECP2 genetic changes that cause the condition, a study revealed. Nerve cells from a rare atypical Rett patient with mild disease and preserved speech had similar core structural…